Article

Warburg Pincus completes Lifecore offer

According to affiliates of private equity firm Warburg Pincus, a tender offer for all outstanding shares of Lifecore Biomedical Inc., a medical materials and device maker, is complete.

New York-According to affiliates of private equity firm Warburg Pincus, a tender offer for all outstanding shares of Lifecore Biomedical Inc., a medical materials and device maker, is complete.

The offer, which was worth $17 per share or about $229.5 million, concluded with about 94.2% of outstanding Lifecore shares tendered.

Investments in health care-related companies around the world add up to $6.2 billion for Warburg Pincus, according to the private equity firm, including $2.7 billion in medical device makers such as American Medical Systems, Bausch & Lomb, ev3, Kyphon, Tornier, and Wright Medical Group.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.